Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Atenativ in heparin-resistant patients undergoing cardiac surgery with cardiopulmonary bypass
2023-507560-39-00Phase 3Authorised
- Sponsor
- Octapharma
- Start
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of antithrombin III concentrate in acquired antithrombin deficiency (AATD) and heparin resistance (3 arms), sponsored by Octapharma. Planned start Aug 2024; status: authorised.
02
Drugs
antithrombin III concentrate
03
Conditions
acquired antithrombin deficiency (AATD)heparin resistance
Beyond the preview
Go deeper on 2023-507560-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507560-39-00.